Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900200 | 0.92 | KCNH2 (0.34) | KCNH2HSP90B1 | |
| SCHEMBL14108423 | 0.91 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL4887120 | 0.89 | KCNH2 (0.35) | KCNH2POLBADRB2HTTSMN1; SMN2 | |
| SCHEMBL4882617 | 0.87 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL4875978 | 0.84 | KCNH2 (0.33) | KCNH2POLBADRB2HTTSMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL4875994 | 0.84 | — | — | |
| SCHEMBL4884582 | 0.81 | TSHR (0.36) | KCNH2HTTSMN1; SMN2TSHR | |
| SCHEMBL4902602 | 0.80 | KCNH2 (0.32) | KCNH2HSP90B1 | |
| SCHEMBL4886717 | 0.79 | LMNA (0.35) | POLBSMN1; SMN2 | |
| SCHEMBL4896799 | 0.78 | KCNH2 (0.30) | KCNH2HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| EP-1838679-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | Pfizer Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072833-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | PFIZER LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | KCNH2 3790/4885HSP90B1 1544/4885TRAP1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.